Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BJTJ-0065
- Development stage
- Preclinical
- Lead developer
- Simcere Pharmaceutical Group
- Modality
- Small Molecules
01
Overview
BJTJ-0065 is an investigational drug candidate currently in preclinical development by Beijing Tuobixi Pharmaceutical (also known as Beijing Tuojie Pharmaceutical). It is being developed for the treatment or prevention of contrast-induced nephropathy (CIN), a form of kidney damage that occurs after exposure to iodine-based contrast media during medical imaging procedures. As part of Beijing Tuobixi's pipeline, which focuses heavily on metabolic, cardiovascular, and renal diseases, BJTJ-0065 represents an early-stage effort to address complications associated with diagnostic and interventional radiology. Specific details regarding its molecular structure and mechanism of action have not yet been publicly disclosed.
Beyond the preview
Go deeper on BJTJ-0065.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BJTJ-0065.